Kim D. Blickenstaff Purchases 1,600,000 Shares of Tandem Diabetes Care Inc (TNDM) Stock

Tandem Diabetes Care Inc (NASDAQ:TNDM) CEO Kim D. Blickenstaff acquired 1,600,000 shares of Tandem Diabetes Care stock in a transaction that occurred on Thursday, March 23rd. The shares were bought at an average price of $1.25 per share, with a total value of $2,000,000.00. Following the transaction, the chief executive officer now directly owns 2,007,939 shares in the company, valued at $2,509,923.75. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Tandem Diabetes Care Inc (NASDAQ:TNDM) opened at 1.25 on Monday. The firm’s 50-day moving average price is $2.18 and its 200-day moving average price is $3.71. The firm’s market cap is $39.17 million. Tandem Diabetes Care Inc has a 12 month low of $1.15 and a 12 month high of $11.30.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Wednesday, March 8th. The medical device company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.17. The firm earned $24.80 million during the quarter, compared to analysts’ expectations of $22.75 million. Tandem Diabetes Care had a negative return on equity of 220.14% and a negative net margin of 95.57%. The company’s revenue for the quarter was down 14.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.40) EPS. Equities research analysts predict that Tandem Diabetes Care Inc will post ($1.88) earnings per share for the current year.

WARNING: “Kim D. Blickenstaff Purchases 1,600,000 Shares of Tandem Diabetes Care Inc (TNDM) Stock” was posted by Mideast Time and is the property of of Mideast Time. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.mideasttime.com/kim-d-blickenstaff-purchases-1600000-shares-of-tandem-diabetes-care-inc-tndm-stock/1588752.html.

TNDM has been the subject of a number of analyst reports. Wedbush restated a “positive” rating on shares of Tandem Diabetes Care in a research report on Tuesday, January 24th. Zacks Investment Research lowered Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research report on Wednesday, March 15th. B. Riley lowered Tandem Diabetes Care from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $5.00 to $1.50 in a research report on Friday. Finally, Northcoast Research reiterated a “buy” rating on shares of Tandem Diabetes Care in a research report on Thursday, March 9th. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $6.21.

Institutional investors have recently bought and sold shares of the stock. Tocqueville Asset Management L.P. boosted its position in Tandem Diabetes Care by 3.0% in the third quarter. Tocqueville Asset Management L.P. now owns 101,400 shares of the medical device company’s stock valued at $777,000 after buying an additional 3,000 shares during the period. State Street Corp boosted its position in Tandem Diabetes Care by 2.5% in the fourth quarter. State Street Corp now owns 232,147 shares of the medical device company’s stock valued at $499,000 after buying an additional 5,645 shares during the period. Iguana Healthcare Management LLC boosted its position in Tandem Diabetes Care by 5.7% in the third quarter. Iguana Healthcare Management LLC now owns 185,000 shares of the medical device company’s stock valued at $1,417,000 after buying an additional 10,000 shares during the period. Keybank National Association OH boosted its position in Tandem Diabetes Care by 99.8% in the fourth quarter. Keybank National Association OH now owns 69,537 shares of the medical device company’s stock valued at $150,000 after buying an additional 34,726 shares during the period. Finally, Wrapmanager Inc. boosted its position in Tandem Diabetes Care by 138.3% in the fourth quarter. Wrapmanager Inc. now owns 60,539 shares of the medical device company’s stock valued at $130,000 after buying an additional 35,135 shares during the period. 56.79% of the stock is owned by hedge funds and other institutional investors.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

5 Day Chart for NASDAQ:TNDM

Receive News & Ratings for Tandem Diabetes Care Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.